PROSTVAC® targeted immunotherapy candidate for prostate cancer.

about

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential The evolution of poxvirus vaccines MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity

P2860

Q26769884-8491F6EA-8CDF-4F0E-8C8B-32F12E69209B Q26995905-2F2EDF4A-371A-4A24-ADC1-674A987B81C4 Q36163830-CAD1BEE5-A31B-4827-AF19-330DD4893D9C

P2860

PROSTVAC® targeted immunotherapy candidate for prostate cancer.

Item

http://www.wikidata.org/entity/Q38206815

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

PROSTVAC® targeted immunotherapy candidate for prostate cancer.

@en

type

Item

label

PROSTVAC® targeted immunotherapy candidate for prostate cancer.

@en

prefLabel

PROSTVAC® targeted immunotherapy candidate for prostate cancer.

@en

P1476

PROSTVAC® targeted immunotherapy candidate for prostate cancer.

@en

P2093

Neal D Shore

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Increased survival with enzalutamide in prostate cancer after chemotherapy

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.

Antigen-processing machinery breakdown and tumor growth.

P304

235-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.13.176

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24762070

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

PROSTVAC® targeted immunotherapy candidate for prostate cancer.

about

P2860

P2860

PROSTVAC® targeted immunotherapy candidate for prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921